Medication adherence is increasingly recognized as an important health care problem. Although various factors have been related to adherence, patients' understanding of their illness and the influence of treatment on it has been shown to affect treatment adherence. Individually tailoring information provided to patients has a greater im-pact on patient behavior than providing generic informatio...

Alzheimer’s disease (AD) causes dementia and continuous damage to brain cells. Cholinesterase inhibitors can alleviate the condition by increasing communication between nerve cells reducing risk of dementia. In an effort treat disease, we synthesized flurbiprofen-based diamines (1,2 diaminoethane 1,3 diaminopropane) Zn(II), Cu(II) metal complexes characterized them single-crystal X-ray analysis...

Cholinergic dysfunction is common to Alzheimer’s dementia and Schizophrenia. The objective of this study is to undertake a systematic review and metaanalysis of the literature on the cognitive and clinical effects of cholinesterase inhibitors administered to patients with schizophrenia and co-morbid Alzheimer’s disease dementia. A literature search of the MEDLINE, CINAHL, PubMed, PsycINFO, EMBA...

People with genetic variants of cholinesterase respond abnormally to succinylcholine, experiencing substantial prolongation of muscle paralysis with apnea rather than the usual 2-6 min. The structure of usual cholinesterase has been determined including the complete amino acid and nucleotide sequence. This has allowed identification of altered amino acids and nucleotides. The variant most frequ...

The cholinesterase activity of the sera of 25 subjects diagnosed as homozygotes for the silent cholinesterase gene was studied by a sensitive enzymatic method employing several thiocholine esters and various inhibitors, and by disc electrophoretic, immunochemical, and chromatographic methods.(a) With one exception, the sera fell into two classes by all criteria. One class (type I, 16 cases) had...

1512 CLINICAL CHEMISTRY, Vol. 25, No. 8, 1979 brano, T., Colorimetric determination of serum cholinesterase and its genetic variants by the propionylthiocholine-dithiobis(nitrobenzoic acid) procedure. Selected Methods Clin. Chem. 8,41-46 (1977). 5. King, J., Studies on human serum cholinesterases. Ph.D. thesis, University of Glasgow, 1974. 6. Garry, P. J., Serum cholinesterase variants: Examina...

Cognitive deficits are commonly associated with maintenance electroconvulsive therapy (ECT). Treatment of these cognitive deficits is important but difficult. Cholinergic pathways are involved in these side effects, and donepezil, a cholinesterase inhibitor, may be useful for improvement of cognition. In this case report, we describe for the first time successful use of donepezil in treating co...

BACKGROUND Previous Cochrane reviews have considered the use of cholinesterase inhibitors in both Parkinson's disease with dementia (PDD) and dementia with Lewy bodies (DLB). The clinical features of DLB and PDD have much in common and are distinguished primarily on the basis of whether or not parkinsonism precedes dementia by more than a year. Patients with both conditions have particularly se...

Displacement of muscarinic radioligands by the cholinesterase inhibitors parathion, paraoxon, physostigmine and phenyl saligenin cyclic phosphate was examined in rat cortex and brain stem, human cortex and brain stem, and in Chinese hamster ovary (CHO) cells expressing human M2 or M4 muscarinic acetylcholine receptors. None of the cholinesterase inhibitors tested significantly affected binding ...

BACKGROUND The effectiveness of the 5 U.S. Food and Drug Administration-approved pharmacologic therapies for dementias in achieving clinically relevant improvements is unclear. PURPOSE To review the evidence for the effectiveness of cholinesterase inhibitors (donepezil, galantamine, rivastigmine, and tacrine) and the neuropeptide-modifying agent memantine in achieving clinically relevant impr...